(Q48531718)

12 February 2018

title

Impact of a five-dimensional framework on R&D productivity at AstraZeneca (English)

1 reference

12 February 2018

10

Ruth E March

1 reference

12 February 2018

Mark Fidock

7

0 references

author name string

Paul Morgan

1

1 reference

12 February 2018

Dean G Brown

2

1 reference

12 February 2018

Simon Lennard

3

1 reference

12 February 2018

Mark J Anderton

4

1 reference

12 February 2018

J Carl Barrett

5

1 reference

12 February 2018

Ulf Eriksson

6

1 reference

12 February 2018

Bengt Hamrén

8

1 reference

12 February 2018

Anthony Johnson

9

1 reference

12 February 2018

James Matcham

11

1 reference

12 February 2018

Jerome Mettetal

12

1 reference

12 February 2018

David J Nicholls

13

1 reference

12 February 2018

Stefan Platz

14

1 reference

12 February 2018

Steve Rees

15

1 reference

12 February 2018

Michael A Snowden

16

1 reference

12 February 2018

Menelas N Pangalos

17

1 reference

12 February 2018

publication date

19 January 2018

1 reference

12 February 2018

Nature Reviews Drug Discovery

published in

1 reference

12 February 2018

Can the pharmaceutical industry reduce attrition rates?

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Why is it hard to terminate failing projects in pharmaceutical R&D?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Diagnosing the decline in pharmaceutical R&D efficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Does size matter in R&D productivity? If not, what does?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Trends in the exploitation of novel drug targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Towards a hit for every target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Pluripotent stem cells in disease modelling and drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

How were new medicines discovered?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Cornerstones of CRISPR-Cas in drug discovery and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Human biological sample biobanking to support tissue biomarkers in pharmaceutical research and development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Chemoproteomic approaches to drug target identification and drug profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Development and applications of CRISPR-Cas9 for genome engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

A TALE nuclease architecture for efficient genome editing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The support of human genetic evidence for approved drug indications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Workflow and metrics for image quality control in large-scale high-content screens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

High throughput screening technologies for ion channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Flow Cytometry: Impact on Early Drug Discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Application of optical biosensors in small-molecule screening activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Novel Acoustic Loading of a Mass Spectrometer: Toward Next-Generation High-Throughput MS Screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Small-molecule inhibitors of protein-protein interactions: progressing toward the reality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The exploration of macrocycles for drug discovery--an underexploited structural class

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Escape from flatland: increasing saturation as an approach to improving clinical success

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Biology-oriented synthesis: harnessing the power of evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

European lead factory opens for business

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Chemical Space of DNA-Encoded Libraries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

DNA-encoded chemistry: enabling the deeper sampling of chemical space

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Twenty years on: the impact of fragments on drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Structural insight into allosteric modulation of protease-activated receptor 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Secondary pharmacology: screening and interpretation of off-target activities - focus on translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Drugging the undruggable RAS: Mission possible?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The chemical evolution of oligonucleotide therapies of clinical utility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Induced protein degradation: an emerging drug discovery paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Small-Molecule PROTACS: New Approaches to Protein Degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Know your target, know your molecule

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The rise of systems pharmacology in drug discovery and development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Model-based drug discovery: implementation and impact.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Recent advances in high throughput screening for ADME properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Critical review of the role of HTS in drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Evolution of ADME science: where else can modeling and simulation contribute?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The right compound in the right assay at the right time: an integrated discovery DMPK strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Reducing the risk of failure: biomarker-guided trial design.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Target organ profiles in toxicity studies supporting human dosing: an assessment of recovery and chronic dosing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD515

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Microfluidic organs-on-chips.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Development of PI3K inhibitors: lessons learned from early clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

MET: a promising anticancer therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

An analytical comparison between point-of-care uric acid testing meters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Targeting eosinophils in allergy, inflammation and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

A decade of innovation in pharmaceutical R&D: the Chorus model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Model-based drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Decision-making in early clinical drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

High-Throughput RT-PCR for small-molecule screening assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.244

7 January 2021

inferred from DOI database lookup

IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells

1 reference

12 December 2020

Rebuilding the R&D engine in big pharma

1 reference

12 December 2020

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

1 reference

12 December 2020

Existing and Emerging Technologies for Point-of-Care Testing

1 reference

12 December 2020

Targeting MET in NSCLC: looking for a needle in a haystack

1 reference

12 December 2020

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen [...]

1 reference

12 December 2020

AstraZeneca launches project to sequence 2 million genomes.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.244

1 reference

12 February 2018

1 reference

12 February 2018